Given that anti-VEGF signaling is an approved therapy for human CRC, we tested if the combination therapy including VEGFR blockade and DKK2 blockade in the MC38 tumor syngeneic graft model could have a synergetic effect. The gene discussed is DKK2; the disease is neoplasm.